The Malaria Vaccine Candidate GMZ2 Elicits Functional Antibodies in Individuals From Malaria Endemic and Non-Endemic Areas

Development and evaluation of a multiplex screening assay for Plasmodium falciparum exposure

(2012) Micha Phill Grønholm Jepsen et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Flow cytometric readout based on Mitotracker Red CMXRos staining of live asexual blood stage malarial parasites reliably assesses antibody dependent cellular inhibition

(2012) Prajakta S Jogdand et al.   MALARIA JOURNAL

Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura

(2012) Meral Esen et al.   VACCINE

Development and Characterization of a Bead-Based, Multiplex Assay for Estimation of Recent HIV Type 1 Infection

(2011) Kelly A. Curtis et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

The Chondroitin Sulfate A-binding Site of the VAR2CSA Protein Involves Multiple N-terminal Domains

(2011) Madeleine Dahlbäck et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations

(2011) Marco Tamborrini et al.   MALARIA JOURNAL

A Randomized Controlled Phase Ib Trial of the Malaria Vaccine Candidate GMZ2 in African Children

(2011) Sabine Bélard et al.   PLoS One

A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 – A GLURP–MSP3 fusion protein malaria vaccine candidate

(2011) Susana Lousada-Dietrich et al.   VACCINE

Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon

(2010) Benjamin Mordmüller et al.   VACCINE

Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso

(2009) I. NEBIE et al.   PARASITE IMMUNOLOGY

The Quantity and Quality of African Children's IgG Responses to Merozoite Surface Antigens Reflect Protection against Plasmodium falciparum Malaria

(2009) David Courtin et al.   PLoS One

Safety and immunogenicity of GMZ2 — a MSP3–GLURP fusion protein malaria vaccine candidate

(2009) Meral Esen et al.   VACCINE

Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria

(2008) Gregory E. D. Mullen et al.   PLoS One